1
|
Bisaccia J, Meyer S, Bertrand-Chapel A, Hecquet Q, Barbet V, Kaniewski B, Léon S, Gadot N, Rochet I, Fajnorova I, Leblond P, Cordier-Bussat M, Corradini N, Vasiljevic A, Billaud M, Picard C, Broutier L, Gallerne C, Dutour A, Blay JY, Castets M. The TLR3 L412F polymorphism prevents TLR3-mediated tumor cell death induction in pediatric sarcomas. Cell Death Discov 2023; 9:230. [PMID: 37414800 DOI: 10.1038/s41420-023-01513-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2023] [Revised: 06/12/2023] [Accepted: 06/21/2023] [Indexed: 07/08/2023] Open
Abstract
Toll-like receptor 3 (TLR3) is a pattern recognition receptor mainly known for its role in innate immune response to infection. Indeed, binding of double-stranded RNA (dsRNA) to TLR3 triggers a pro-inflammatory cascade leading to cytokine release and immune cell activation. Its anti-tumoral potential has emerged progressively, associated with a direct impact on tumor cell death induction and with an indirect action on immune system reactivation. Accordingly, TLR3 agonists are currently being tested in clinical trials for several adult cancers. Meanwhile, TLR3 variants have been linked to auto-immune disorders, and as risk factors of viral infection and cancers. However, aside from neuroblastoma, TLR3 role in childhood cancers has not been evaluated. Here, by integrating public transcriptomic data of pediatric tumors, we unveil that high TLR3 expression is largely associated with a better prognosis in childhood sarcomas. Using osteosarcomas and rhabdomyosarcomas as models, we show that TLR3 efficiently drives tumor cell death in vitro and induces tumor regression in vivo. Interestingly, this anti-tumoral effect was lost in cells expressing the homozygous TLR3 L412F polymorphism, which is enriched in a rhabdomyosarcomas cohort. Thus, our results demonstrate the therapeutic potential associated with the targeting of TLR3 in pediatric sarcomas, but also the need to stratify patients eligible for this clinical approach with respect to the TLR3 variants expressed.
Collapse
Affiliation(s)
- Joseph Bisaccia
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Swann Meyer
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Adrien Bertrand-Chapel
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Quentin Hecquet
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Virginie Barbet
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Bastien Kaniewski
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Sophie Léon
- EX-VIVO Platform, Université de Lyon, Université Claude Bernard de Lyon, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon (CRCL), Lyon, France
| | - Nicolas Gadot
- Anatomopathology Research Platform, Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France
| | - Isabelle Rochet
- Department of Pathology, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Université de Lyon, Lyon, France
| | - Iveta Fajnorova
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Pierre Leblond
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
- Department of Pediatric Oncology, Institut d'hématologie et d'oncologie pédiatrique, Centre Léon Bérard, Lyon, France
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France
- Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France
| | - Martine Cordier-Bussat
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France
| | - Nadège Corradini
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
- Department of Pediatric Oncology, Institut d'hématologie et d'oncologie pédiatrique, Centre Léon Bérard, Lyon, France
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France
- Department of Pediatric Oncology, Institut d'Hématologie et d'Oncologie Pédiatrique, Centre Léon Bérard, Lyon, France
| | - Alexandre Vasiljevic
- Department of Pathology, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Université de Lyon, Lyon, France
| | - Marc Billaud
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France
| | - Cécile Picard
- Department of Pathology, Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Université de Lyon, Lyon, France
| | - Laura Broutier
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France
| | - Cindy Gallerne
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
| | - Aurélie Dutour
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France
| | - Jean-Yves Blay
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France
| | - Marie Castets
- Cell Death and Childhood Cancers Laboratory, LabEx DEV2CAN, Centre de Recherche en Cancérologie de Lyon, INSERM U1052- CNRS UMR5286, Université Claude Bernard de Lyon, Centre Léon Bérard, Institut Convergence Plascan, Lyon, France.
- Department of Translational Research in Paediatric Oncology, Centre Léon Bérard, Lyon, France.
| |
Collapse
|
2
|
Prola A, Blondelle J, Vandestienne A, Piquereau J, Denis RGP, Guyot S, Chauvin H, Mourier A, Maurer M, Henry C, Khadhraoui N, Gallerne C, Molinié T, Courtin G, Guillaud L, Gressette M, Solgadi A, Dumont F, Castel J, Ternacle J, Demarquoy J, Malgoyre A, Koulmann N, Derumeaux G, Giraud MF, Joubert F, Veksler V, Luquet S, Relaix F, Tiret L, Pilot-Storck F. Cardiolipin content controls mitochondrial coupling and energetic efficiency in muscle. Sci Adv 2021; 7:7/1/eabd6322. [PMID: 33523852 PMCID: PMC7775760 DOI: 10.1126/sciadv.abd6322] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Accepted: 11/04/2020] [Indexed: 05/11/2023]
Abstract
Unbalanced energy partitioning participates in the rise of obesity, a major public health concern in many countries. Increasing basal energy expenditure has been proposed as a strategy to fight obesity yet raises efficiency and safety concerns. Here, we show that mice deficient for a muscle-specific enzyme of very-long-chain fatty acid synthesis display increased basal energy expenditure and protection against high-fat diet-induced obesity. Mechanistically, muscle-specific modulation of the very-long-chain fatty acid pathway was associated with a reduced content of the inner mitochondrial membrane phospholipid cardiolipin and a blunted coupling efficiency between the respiratory chain and adenosine 5'-triphosphate (ATP) synthase, which was restored by cardiolipin enrichment. Our study reveals that selective increase of lipid oxidative capacities in skeletal muscle, through the cardiolipin-dependent lowering of mitochondrial ATP production, provides an effective option against obesity at the whole-body level.
Collapse
Affiliation(s)
- Alexandre Prola
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Jordan Blondelle
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Aymeline Vandestienne
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Jérôme Piquereau
- UMR-S 1180, INSERM, Université Paris-Sud, Université Paris-Saclay, F-92296 Châtenay-Malabry, France
| | | | - Stéphane Guyot
- Université Bourgogne Franche-Comté, AgroSup Dijon, PAM UMR A 02.102, F-21000 Dijon, France
| | - Hadrien Chauvin
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Arnaud Mourier
- Université Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France
| | - Marie Maurer
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Céline Henry
- PAPPSO, Université Paris-Saclay, INRAE, AgroParisTech, Micalis Institute, F-78350 Jouy-en-Josas, France
| | - Nahed Khadhraoui
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Cindy Gallerne
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Thibaut Molinié
- Université Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France
| | - Guillaume Courtin
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Laurent Guillaud
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Mélanie Gressette
- UMR-S 1180, INSERM, Université Paris-Sud, Université Paris-Saclay, F-92296 Châtenay-Malabry, France
| | - Audrey Solgadi
- UMS IPSIT, Université Paris-Saclay, F-92296 Châtenay-Malabry, France
| | - Florent Dumont
- UMS IPSIT, Université Paris-Saclay, F-92296 Châtenay-Malabry, France
| | - Julien Castel
- Université de Paris, BFA, UMR 8251, CNRS, F-75014 Paris, France
| | - Julien Ternacle
- Université Paris-Est Créteil, INSERM, IMRB, Team Derumeaux, F-94010 Creteil, France
| | - Jean Demarquoy
- Université Bourgogne Franche-Comté, AgroSup Dijon, PAM UMR A 02.102, F-21000 Dijon, France
| | - Alexandra Malgoyre
- Département Environnements Opérationnels, Unité de Physiologie des Exercices et Activités en Conditions Extrêmes, Institut de Recherche Biomédicale des Armées, F-91220 Brétigny-Sur-Orge, France
- LBEPS, Université Evry, IRBA, Université Paris-Saclay, F-91025 Evry, France
| | - Nathalie Koulmann
- Département Environnements Opérationnels, Unité de Physiologie des Exercices et Activités en Conditions Extrêmes, Institut de Recherche Biomédicale des Armées, F-91220 Brétigny-Sur-Orge, France
- LBEPS, Université Evry, IRBA, Université Paris-Saclay, F-91025 Evry, France
- École du Val de Grâce, Place Alphonse Laveran, F-75005 Paris, France
| | - Geneviève Derumeaux
- Université Paris-Est Créteil, INSERM, IMRB, Team Derumeaux, F-94010 Creteil, France
| | | | - Frédéric Joubert
- Laboratoire Jean Perrin, CNRS, Sorbonne Université, UMR 8237, Paris, F-75005, France
| | - Vladimir Veksler
- UMR-S 1180, INSERM, Université Paris-Sud, Université Paris-Saclay, F-92296 Châtenay-Malabry, France
| | - Serge Luquet
- Université de Paris, BFA, UMR 8251, CNRS, F-75014 Paris, France
| | - Frédéric Relaix
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France.
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Laurent Tiret
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France.
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| | - Fanny Pilot-Storck
- Université Paris-Est Créteil, INSERM, IMRB, Team Relaix, F-94010 Créteil, France.
- EnvA, IMRB, F-94700 Maisons-Alfort, France
- EFS, IMRB, F-94010 Créteil, France
| |
Collapse
|
3
|
Hasmim M, Bruno S, Azzi S, Gallerne C, Michel JG, Chiabotto G, Lecoz V, Romei C, Spaggiari GM, Pezzolo A, Pistoia V, Angevin E, Gad S, Ferlicot S, Messai Y, Kieda C, Clay D, Sabatini F, Escudier B, Camussi G, Eid P, Azzarone B, Chouaib S. Isolation and characterization of renal cancer stem cells from patient-derived xenografts. Oncotarget 2017; 7:15507-24. [PMID: 26551931 PMCID: PMC4941257 DOI: 10.18632/oncotarget.6266] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Accepted: 10/08/2015] [Indexed: 01/06/2023] Open
Abstract
As rapidly developing patient-derived xenografts (PDX) could represent potential sources of cancer stem cells (CSC), we selected and characterized non-cultured PDX cell suspensions from four different renal carcinomas (RCC). Only the cell suspensions from the serial xenografts (PDX-1 and PDX-2) of an undifferentiated RCC (RCC-41) adapted to the selective CSC medium. The cell suspension derived from the original tumor specimen (RCC-41-P-0) did not adapt to the selective medium and strongly expressed CSC-like markers (CD133 and CD105) together with the non-CSC tumor marker E-cadherin. In comparison, PDX-1 and PDX-2 cells exhibited evolution in their phenotype since PDX-1 cells were CD133high/CD105-/Ecadlow and PDX-2 cells were CD133low/CD105-/Ecad-. Both PDX subsets expressed additional stem cell markers (CD146/CD29/OCT4/NANOG/Nestin) but still contained non-CSC tumor cells. Therefore, using different cell sorting strategies, we characterized 3 different putative CSC subsets (RCC-41-PDX-1/CD132+, RCC-41-PDX-2/CD133-/EpCAMlow and RCC-41-PDX-2/CD133+/EpCAMbright). In addition, transcriptomic analysis showed that RCC-41-PDX-2/CD133− over-expressed the pluripotency gene ERBB4, while RCC-41-PDX-2/CD133+ over-expressed several tumor suppressor genes. These three CSC subsets displayed ALDH activity, formed serial spheroids and developed serial tumors in SCID mice, although RCC-41-PDX-1/CD132+ and RCC-41-PDX-2/CD133+ displayed less efficiently the above CSC properties. RCC-41-PDX-1/CD132+ tumors showed vessels of human origin with CSC displaying peri-vascular distribution. By contrast, RCC-41-PDX-2 originated tumors exhibiting only vessels of mouse origin without CSC peri-vascular distribution. Altogether, our results indicate that PDX murine microenvironment promotes a continuous redesign of CSC phenotype, unmasking CSC subsets potentially present in a single RCC or generating ex novo different CSC-like subsets.
Collapse
Affiliation(s)
- Meriem Hasmim
- INSERM U 1186, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy Campus, Villejuif, France.,INSERM UMR 1014, Lavoisier Building, Paul Brousse Hospital, Villejuif, France
| | - Stefania Bruno
- Department of Molecular Biotechnology and Healthy Science, Molecular Biotechnology Center, University of Torino, Turin, Italy
| | - Sandy Azzi
- INSERM UMR 1014, Lavoisier Building, Paul Brousse Hospital, Villejuif, France
| | - Cindy Gallerne
- INSERM UMR 1014, Lavoisier Building, Paul Brousse Hospital, Villejuif, France
| | - Julien Giron Michel
- INSERM UMR 1014, Lavoisier Building, Paul Brousse Hospital, Villejuif, France
| | - Giulia Chiabotto
- Department of Medical Science, University of Torino, Medical School, Torino, Italy
| | - Vincent Lecoz
- INSERM UMR 1014, Lavoisier Building, Paul Brousse Hospital, Villejuif, France
| | | | | | | | - Vito Pistoia
- Laboratory of Oncology Giannina Gaslini Institute, Genoa, Italy
| | - Eric Angevin
- INSERM U 1186, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy Campus, Villejuif, France.,Medical Oncology Department, Gustave Roussy Campus, Villejuif, France
| | - Sophie Gad
- INSERM U 1186, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy Campus, Villejuif, France.,Laboratoire de Génétique Oncologique EPHE, Ecole Pratique des Hautes Etudes, Paris, France
| | - Sophie Ferlicot
- INSERM U 1186, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy Campus, Villejuif, France.,Université Paris-Sud, Assistance Publique-Hôpitaux de Paris, Service d'Anatomo-Pathologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Yosra Messai
- INSERM U 1186, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy Campus, Villejuif, France
| | - Claudine Kieda
- Centre de Biophysique Moléculaire, CNRS UPR 4301, Orléans, France
| | - Denis Clay
- INSERM UMR 972, Paul Brousse Hospital, Villejuif, France
| | - Federica Sabatini
- Stem Cell and Cell Therapy Laboratory, Istituto G. Gaslini, Genoa, Italy
| | - Bernard Escudier
- INSERM U 1186, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy Campus, Villejuif, France.,Medical Oncology Department, Gustave Roussy Campus, Villejuif, France
| | - Giovanni Camussi
- Department of Medical Science, University of Torino, Medical School, Torino, Italy
| | - Pierre Eid
- INSERM UMR 1014, Lavoisier Building, Paul Brousse Hospital, Villejuif, France
| | | | - Salem Chouaib
- INSERM U 1186, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy Campus, Villejuif, France
| |
Collapse
|
4
|
da Silva JP, Prola A, Guilbert A, Lecru L, Piquereau J, Ribeiro M, Mateo P, Gressette M, Gallerne C, François H, Eid P, Ventura-Clapier R, Garnier A, Lemaire C. SIRT1 protects the heart from endoplasmic reticulum stress-induced apoptosis through eIF2α deacetylation. Archives of Cardiovascular Diseases Supplements 2017. [DOI: 10.1016/s1878-6480(17)30429-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Le Coz V, Zhu C, Devocelle A, Vazquez A, Boucheix C, Azzi S, Gallerne C, Eid P, Lecourt S, Giron-Michel J. IGF-1 contributes to the expansion of melanoma-initiating cells through an epithelial-mesenchymal transition process. Oncotarget 2016; 7:82511-82527. [PMID: 27764776 PMCID: PMC5347710 DOI: 10.18632/oncotarget.12733] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2016] [Accepted: 10/12/2016] [Indexed: 01/16/2023] Open
Abstract
Melanoma is a particularly virulent human cancer, due to its resistance to conventional treatments and high frequency of metastasis. Melanomas contain a fraction of cells, the melanoma-initiating cells (MICs), responsible for tumor propagation and relapse. Identification of the molecular pathways supporting MICs is, therefore, vital for the development of targeted treatments. One factor produced by melanoma cells and their microenvironment, insulin-like growth factor-1 (IGF- 1), is linked to epithelial-mesenchymal transition (EMT) and stemness features in several cancers.We evaluated the effect of IGF-1 on the phenotype and chemoresistance of B16-F10 cells. IGF-1 inhibition in these cells prevented malignant cell proliferation, migration and invasion, and lung colony formation in immunodeficient mice. IGF-1 downregulation also markedly inhibited EMT, with low levels of ZEB1 and mesenchymal markers (N-cadherin, CD44, CD29, CD105) associated with high levels of E-cadherin and MITF, the major regulator of melanocyte differentiation. IGF-1 inhibition greatly reduced stemness features, including the expression of key stem markers (SOX2, Oct-3/4, CD24 and CD133), and the functional characteristics of MICs (melanosphere formation, aldehyde dehydrogenase activity, side population). These features were associated with a high degree of sensitivity to mitoxantrone treatment.In this study, we deciphered new connections between IGF-1 and stemness features and identified IGF-1 as instrumental for maintaining the MIC phenotype. The IGF1/IGF1-R nexus could be targeted for the development of more efficient anti-melanoma treatments. Blocking the IGF-1 pathway would improve the immune response, decrease the metastatic potential of tumor cells and sensitize melanoma cells to conventional treatments.
Collapse
Affiliation(s)
- Vincent Le Coz
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Chaobin Zhu
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Aurore Devocelle
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Aimé Vazquez
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Claude Boucheix
- INSERM UMRS 1193, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Sandy Azzi
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Cindy Gallerne
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Pierre Eid
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Séverine Lecourt
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| | - Julien Giron-Michel
- INSERM UMRS 1197, Hôpital Paul Brousse, 94807 Villejuif Cedex, France
- Université Paris-Saclay, 91190, France
| |
Collapse
|
6
|
Azzi S, Gallerne C, Romei C, Le Coz V, Gangemi R, Khawam K, Devocelle A, Gu Y, Bruno S, Ferrini S, Chouaib S, Eid P, Azzarone B, Giron-Michel J. Human Renal Normal, Tumoral, and Cancer Stem Cells Express Membrane-Bound Interleukin-15 Isoforms Displaying Different Functions. Neoplasia 2016; 17:509-17. [PMID: 26152359 PMCID: PMC4719000 DOI: 10.1016/j.neo.2015.06.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Revised: 05/28/2015] [Accepted: 06/03/2015] [Indexed: 01/01/2023] Open
Abstract
Intrarenal interleukin-15 (IL-15) participates to renal pathophysiology, but the role of its different membrane-bound isoforms remains to be elucidated. In this study, we reassess the biology of membrane-bound IL-15 (mb-IL-15) isoforms by comparing primary cultures of human renal proximal tubular epithelial cells (RPTEC) to peritumoral (ptumTEC), tumoral (RCC), and cancer stem cells (CSC/CD105+). RPTEC express a 14 to 16 kDa mb-IL-15, whose existence has been assumed but never formally demonstrated and likely represents the isoform anchored at the cell membrane through the IL-15 receptor α (IL-15Rα) chain, because it is sensitive to acidic treatment and is not competent to deliver a reverse signal. By contrast, ptumTEC, RCC, and CSC express a novel N-hyperglycosylated, short-lived transmembrane mb-IL-15 (tmb-IL-15) isoform around 27 kDa, resistant to acidic shock, delivering a reverse signal in response to its soluble receptor (sIL-15Rα). This reverse signal triggers the down-regulation of the tumor suppressor gene E-cadherin in ptumTEC and RCC but not in CSC/CD105+, where it promotes survival. Indeed, through the AKT pathway, tmb-IL-15 protects CSC/CD105+ from non-programmed cell death induced by serum starvation. Finally, both mb-IL-15 and tmb-IL-15 are sensitive to metalloproteases, and the cleaved tmb-IL-15 (25 kDa) displays a powerful anti-apoptotic effect on human hematopoietic cells. Overall, our data indicate that both mb-IL-15 and tmb-IL-15 isoforms play a complex role in renal pathophysiology downregulating E-cadherin and favoring cell survival. Moreover, “apparently normal” ptumTEC cells, sharing different properties with RCC, could contribute to organize an enlarged peritumoral “preneoplastic” environment committed to favor tumor progression.
Collapse
Affiliation(s)
- Sandy Azzi
- INSERM UMR 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud (Paris 11), Orsay, France
| | - Cindy Gallerne
- INSERM UMR 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud (Paris 11), Orsay, France
| | - Cristina Romei
- Department of Clinical and Experimental Immunology, Istituto G. Gaslini, Genoa, Italy
| | - Vincent Le Coz
- INSERM UMR 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud (Paris 11), Orsay, France
| | - Rosaria Gangemi
- Biotherapy Unit, IRCCS A.O.U. San Martino-IST, Largo R. Benzi 10, Genoa, Italy
| | - Krystel Khawam
- INSERM UMR 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud (Paris 11), Orsay, France
| | - Aurore Devocelle
- INSERM UMR 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud (Paris 11), Orsay, France
| | - Yanhong Gu
- Department of Oncology and Department of Experimental Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - Stefania Bruno
- Department of Molecular Biotechnologies and Health Sciences, Molecular Biotechnology Center, University of Torino, Turin, Italy
| | - Silvano Ferrini
- Biotherapy Unit, IRCCS A.O.U. San Martino-IST, Largo R. Benzi 10, Genoa, Italy
| | - Salem Chouaib
- INSERM UMR 753, Université de Paris-Sud, Institut Gustave Roussy, Villejuif, France
| | - Pierre Eid
- INSERM UMR 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud (Paris 11), Orsay, France
| | - Bruno Azzarone
- Department of Clinical and Experimental Immunology, Istituto G. Gaslini, Genoa, Italy.
| | - Julien Giron-Michel
- INSERM UMR 1014, Hôpital Paul Brousse, Villejuif, France; Université Paris-Sud (Paris 11), Orsay, France.
| |
Collapse
|
7
|
Bensassi F, Gallerne C, Sharaf el dein O, Rabeh Hajlaoui M, Bacha H, Lemaire C. Combined effects of alternariols mixture on human colon carcinoma cells. Toxicol Mech Methods 2014; 25:56-62. [DOI: 10.3109/15376516.2014.985354] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
8
|
Tufo G, Jones AWE, Wang Z, Hamelin J, Tajeddine N, Esposti DD, Martel C, Boursier C, Gallerne C, Migdal C, Lemaire C, Szabadkai G, Lemoine A, Kroemer G, Brenner C. The protein disulfide isomerases PDIA4 and PDIA6 mediate resistance to cisplatin-induced cell death in lung adenocarcinoma. Cell Death Differ 2014; 21:685-95. [PMID: 24464223 PMCID: PMC3978299 DOI: 10.1038/cdd.2013.193] [Citation(s) in RCA: 96] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Revised: 11/14/2013] [Accepted: 12/02/2013] [Indexed: 01/03/2023] Open
Abstract
Intrinsic and acquired chemoresistance are frequent causes of cancer eradication failure. Thus, long-term cis-diaminedichloroplatine(II) (CDDP) or cisplatin treatment is known to promote tumor cell resistance to apoptosis induction via multiple mechanisms involving gene expression modulation of oncogenes, tumor suppressors and blockade of pro-apoptotic mitochondrial membrane permeabilization. Here, we demonstrate that CDDP-resistant non-small lung cancer cells undergo profound remodeling of their endoplasmic reticulum (ER) proteome (>80 proteins identified by proteomics) and exhibit a dramatic overexpression of two protein disulfide isomerases, PDIA4 and PDIA6, without any alteration in ER-cytosol Ca(2+) fluxes. Using pharmacological and genetic inhibition, we show that inactivation of both proteins directly stimulates CDDP-induced cell death by different cellular signaling pathways. PDIA4 inactivation restores a classical mitochondrial apoptosis pathway, while knockdown of PDIA6 favors a non-canonical cell death pathway sharing some necroptosis features. Overexpression of both proteins has also been found in lung adenocarcinoma patients, suggesting a clinical importance of these proteins in chemoresistance.
Collapse
Affiliation(s)
- G Tufo
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| | - A W E Jones
- Department of Cell and Developmental Biology, University College London, London, UK
| | - Z Wang
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| | - J Hamelin
- APHP Hôpital P. Brousse, Biochimie et oncogénétique, INSERM U1004, Villejuif, France
| | - N Tajeddine
- INSERM U848, Institut Gustave Roussy, Université Paris-Sud 11, PR1, 39 rue Camille Desmoulins, Villejuif, France
| | - D D Esposti
- APHP Hôpital P. Brousse, Biochimie et oncogénétique, INSERM U1004, Villejuif, France
| | - C Martel
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
- Montreal Heart Institute, Centre de Recherche, Montreal, Quebec, Canada
| | | | - C Gallerne
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| | - C Migdal
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
- INSERM U 996, Châtenay-Malabry, France
| | - C Lemaire
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Department of Biology, University of Versailles–St Quentin, Versailles, France
| | - G Szabadkai
- Department of Cell and Developmental Biology, University College London, London, UK
- Department of Biomedical Sciences, University of Padua, Padua, Italy
| | - A Lemoine
- APHP Hôpital P. Brousse, Biochimie et oncogénétique, INSERM U1004, Villejuif, France
| | - G Kroemer
- INSERM U848, Institut Gustave Roussy, Université Paris-Sud 11, PR1, 39 rue Camille Desmoulins, Villejuif, France
- Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France
- Metabolomics Platform, Institut Gustave Roussy, Villejuif, France
- Equipe 11 labellisée par la Ligue contre le Cancer, Centre de Recherche des Cordeliers, Paris, France
- Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France
| | - C Brenner
- INSERM UMR-S 769, LabEx LERMIT, Châtenay-Malabry, France
- Faculté de Pharmacie, Université de Paris-Sud, Châtenay-Malabry, France
| |
Collapse
|
9
|
Gallerne C, Touat Z, Chen ZX, Martel C, Mayola E, el dein OS, Buron N, Le Bras M, Jacotot E, Borgne-Sanchez A, Lemoine A, Lemaire C, Pervaiz S, Brenner C. Corrigendum to “The fourth isoform of the adenine nucleotide translocator inhibits mitochondrial apoptosis in cancer cells” [Int. J. Biochem. Cell Biol. 42 (2010) 623–629]. Int J Biochem Cell Biol 2014. [DOI: 10.1016/j.biocel.2013.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
10
|
Gallerne C, Prola A, Lemaire C. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta 2013; 1833:1356-66. [PMID: 23485394 DOI: 10.1016/j.bbamcr.2013.02.014] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2012] [Revised: 01/17/2013] [Accepted: 02/15/2013] [Indexed: 01/06/2023]
Abstract
Heat shock protein 90 (Hsp90) has recently emerged as an attractive therapeutic target in cancer treatment because of its role in stabilizing the active form of a wide range of client oncoproteins. This study investigated the mechanism of apoptosis induced by the purine-scaffold Hsp90 inhibitor PU-H71 in different human cancer cell lines and examined the role of Bcl-2 and Bax in this process. We demonstrated that Hsp90 inhibition by PU-H71 generated endoplasmic reticulum (ER) stress and activated the Unfolded Protein Response (UPR) as evidenced by XBP1 mRNA splicing and up-regulation of Grp94, Grp78, ATF4 and CHOP. In response to PU-H71-induced ER stress, apoptosis was triggered in melanoma, cervix, colon, liver and lung cancer cells, but not in normal human fibroblasts. Apoptosis was executed through the mitochondrial pathway as shown by down-regulation of Bcl-2, up-regulation and activation of Bax, permeabilization of mitochondrial membranes, release of cytochrome c and activation of caspases. We also found that, in contrast to the ER stressor thapsigargin, PU-H71 induced apoptosis in cells overexpressing Bcl-2 and thus overcame the resistance conferred by this anti-apoptotic protein. In addition, although Bax deficiency rendered cells resistant to PU-H71, combined treatment with the anticancer drugs cisplatin or melphalan greatly sensitized these cells to PU-H71. Taken together, these data suggest that inhibition of Hsp90 by PU-H71 is a promising strategy for cancer treatment, particularly in the case of tumors resistant to conventional chemotherapy.
Collapse
Affiliation(s)
- Cindy Gallerne
- INSERM UMR S-769, LabEx LERMIT, Châtenay-Malabry, France
| | | | | |
Collapse
|
11
|
Bensassi F, Gallerne C, Sharaf El Dein O, Lemaire C, Hajlaoui MR, Bacha H. Involvement of mitochondria-mediated apoptosis in deoxynivalenol cytotoxicity. Food Chem Toxicol 2012; 50:1680-9. [DOI: 10.1016/j.fct.2012.01.015] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Revised: 01/05/2012] [Accepted: 01/10/2012] [Indexed: 10/14/2022]
|
12
|
Sharaf el dein O, Gallerne C, Brenner C, Lemaire C. Increased expression of VDAC1 sensitizes carcinoma cells to apoptosis induced by DNA cross-linking agents. Biochem Pharmacol 2012; 83:1172-82. [PMID: 22285227 DOI: 10.1016/j.bcp.2012.01.017] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2011] [Revised: 01/12/2012] [Accepted: 01/13/2012] [Indexed: 11/30/2022]
Abstract
A major clinical problem regarding antitumoral treatment with DNA cross-linking agents such as cisplatin (Cisp), mechlorethamine (HN2) or its derivative melphalan (MLP) is intrinsic or acquired resistance to therapy, which frequently results from a resistance to apoptosis induction. In this study, aimed to identify novel sensitizing targets to DNA cross-linker-induced cell death, we demonstrated that MLP, Cisp and HN2 induce mitochondrial permeability transition pore (PTP)-mediated apoptosis in cervical and colon carcinoma cells. This apoptotic pathway is characterized by dissipation of the mitochondrial membrane potential, production of ROS, mitochondrial translocation of Bax, release of apoptogenic factors, caspase activation and nuclear alterations. The opening of PTP and subsequent apoptosis was reduced in Bax deficient cells and in cells with elevated Bcl-2 level, but not in cells invalidated for Bak. We further showed that, among the pro-apoptotic PTP regulators tested (VDAC1, creatine kinase, ANT1 and ANT3), exogenous overexpression of VDAC1 was the most effective in enhancing Cisp- and MLP-induced apoptosis. In addition, pharmacologically induced up-regulation of VDAC1 by the chemotherapeutic agent arsenic trioxide (As(2)O(3)) greatly sensitized HeLa cells to Cisp and MLP treatment. These data indicate that increased expression of VDAC1 appears as a promising strategy to improve DNA cross-linker-induced chemotherapy.
Collapse
Affiliation(s)
- Ossama Sharaf el dein
- INSERM UMR-S 769, LabEx LERMIT, Université Paris-Sud 11, 5 rue J B Clement, Chatenay-Malabry, France.
| | | | | | | |
Collapse
|
13
|
Mayola E, Gallerne C, Esposti DD, Martel C, Pervaiz S, Larue L, Debuire B, Lemoine A, Brenner C, Lemaire C. Withaferin A induces apoptosis in human melanoma cells through generation of reactive oxygen species and down-regulation of Bcl-2. Apoptosis 2012; 16:1014-27. [PMID: 21710254 DOI: 10.1007/s10495-011-0625-x] [Citation(s) in RCA: 107] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
A high resistance and heterogeneous response to conventional anti-cancer chemotherapies characterize malignant cutaneous melanoma, the most aggressive and deadly form of skin cancer. Withaferin A (WFA), a withanolide derived from the medicinal plant Withania somnifera, has been reported for its anti-tumorigenic activity against various cancer cells. For the first time, we examined the death-inducing potential of WFA against a panel of four different human melanoma cells and investigated the cellular mechanisms involved. WFA induces apoptotic cell death with various IC50 ranging from 1.8 to 6.1 μM. The susceptibility of cells toward WFA-induced apoptosis correlated with low Bcl-2/Bax and Bcl-2/Bim ratios. In all cell lines, the apoptotic process triggered by WFA involves the mitochondrial pathway and was associated with Bcl-2 down regulation, Bax mitochondrial translocation, cytochrome c release into the cytosol, transmembrane potential (ΔΨm) dissipation, caspase 9 and caspase 3 activation and DNA fragmentation. WFA cytotoxicity requires early reactive oxygen species (ROS) production and glutathione depletion, the inhibition of ROS increase by the antioxidant N-acetylcysteine resulting in complete suppression of mitochondrial and nuclear events. Altogether, these results support the therapeutic potential of WFA against human melanoma.
Collapse
Affiliation(s)
- Eleonore Mayola
- INSERM UMR S-769, Université Paris-Sud 11, 5 rue JB Clément, 92296, Châtenay-Malabry, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Bensassi F, Gallerne C, dein OSE, Hajlaoui MR, Bacha H, Lemaire C. Mechanism of Alternariol monomethyl ether-induced mitochondrial apoptosis in human colon carcinoma cells. Toxicology 2011; 290:230-40. [DOI: 10.1016/j.tox.2011.09.087] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2011] [Revised: 09/28/2011] [Accepted: 09/30/2011] [Indexed: 10/16/2022]
|
15
|
Gallerne C, Touat Z, Chen ZX, Martel C, Mayola E, Sharaf el dein O, Buron N, Le Bras M, Jacotot E, Borgne-Sanchez A. The fourth isoform of the adenine nucleotide translocator inhibits mitochondrial apoptosis in cancer cells. Int J Biochem Cell Biol 2010; 42:623-9. [DOI: 10.1016/j.biocel.2009.12.024] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2009] [Revised: 12/18/2009] [Accepted: 12/24/2009] [Indexed: 11/27/2022]
|